Fluoroquinolones
A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Pharmacology".
Deadline for manuscript submissions: 31 March 2025 | Viewed by 322
Special Issue Editors
Interests: vagus nerve; neurogastroenterology; fluoroquinolones
Interests: organic chemistry; medicinal chemistry; carbohydrate and nucleos(t)ide chemistry; bioactive molecules; enzyme inhibitors; anticancer agents; antimicrobial agents; anti-Alzheimer’s agents
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
You are invited to submit a manuscript for a Special Issue of Pharmaceuticals on fluoroquinolones.
Fluoroquinolones are a class of antibiotics widely used to treat various bacterial infections due to their broad spectrum of activity. They are effective against many types of bacteria, including those causing respiratory, urinary tract, gastrointestinal, and skin infections. Common fluoroquinolones include ciprofloxacin, levofloxacin, and moxifloxacin.
While fluoroquinolones are generally effective and well-tolerated, they are associated with a rare but serious side effect known as fluoroquinolone-associated disability (FQAD). FQAD encompasses a range of symptoms that can persist long after discontinuation of the medication. These symptoms may include severe fatigue, muscle weakness, joint pain, nerve damage, cognitive difficulties, and psychiatric disturbances. Since the discovery of FQAD, fluoroquinolones have received a “Black Box” label, warning clinicians worldwide to prescribe these antibiotics for uncommon infections or for infections that have not resolved with the utilization of other antibiotic drugs; yet, fluoroquinolones are still among the most prescribed antibiotics worldwide.
The exact mechanism behind FQAD is not fully understood, but it is believed to involve mitochondrial dysfunction, oxidative stress, and damage to connective tissues and nerves. Certain individuals may be predisposed to developing FQAD due to genetic factors or underlying health conditions.
The risk of FQAD is generally higher in older adults, those with a history of tendon disorders, and individuals taking corticosteroids or concurrently using other medications that affect the central nervous system. Symptoms of FQAD can range from mild discomfort to debilitating disability, severely impacting the quality of life of affected individuals.
Dr. Cecilia Bove
Dr. Nuno Manuel Xavier
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- fluoroquinolones
- fluoroquinolone-associated disability
- antibiotic safety
- fluoroquinolone toxicity
- antibiotic stewardship
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.